Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
New Stanford initiative aims to build digital twin of human brain
The effort, funded by private donors, seeks to train the model on a trove of MRI and magnetoencephalography data that scientists plan to collect over the next five years—but questions about its scientific utility and feasibility remain.
New Stanford initiative aims to build digital twin of human brain
The effort, funded by private donors, seeks to train the model on a trove of MRI and magnetoencephalography data that scientists plan to collect over the next five years—but questions about its scientific utility and feasibility remain.
The genome offers a recipe, not a blueprint, for the brain
During brain development, genes set the rules and turn the knobs; self-organization does much of the rest.
The genome offers a recipe, not a blueprint, for the brain
During brain development, genes set the rules and turn the knobs; self-organization does much of the rest.
Autism research involving monkeys contends with uphill battle
Macaques and marmosets recapitulate the condition’s core traits better than mice can, but funding uncertainty and challenges at primate centers in the United States could make this work difficult to continue.
Autism research involving monkeys contends with uphill battle
Macaques and marmosets recapitulate the condition’s core traits better than mice can, but funding uncertainty and challenges at primate centers in the United States could make this work difficult to continue.